Thursday, January 18, 2018 10:09:39 AM
BY Market Wire
HOUSTON, TX -- (Marketwired) -- 01/17/18 -- Moleculin Biotech, Inc. (MBRX), ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced the expansion of its Science Advisory Board to include Drs. Jorge Cortes and Elihu Estey.
"We are honored to have two more distinguished clinicians join our Science Advisory Board," commented Walter Klemp, Chairman and CEO of Moleculin. "Their expertise in Acute Myeloid Leukemia ("AML") reflects the importance of our clinical trial of Annamycin and our recent announcement to expand clinical research in AML with our immuno-stimulating STAT3 inhibitor, WP1066."
Jorge Cortes, M.D., is deputy chair and professor of medicine in the Department of Leukemia at MD Anderson Cancer Center where he directs the CML and AML Programs. Dr. Cortes received his medical degree in 1986 from the Universidad Nacional Autonoma de Mexico, and has been at MD Anderson since 1991. Dr. Cortes, whose clinical interest focuses on new drug development and the management of patients with myelodysplatic syndromes, acute and chronic leukemias, and myeloproliferative disorders has authored over 900 peer-reviewed medical publications in top-tier journals including New England Journal of Medicine, Lancet Oncology, Lancet Hematology, Journal of Clinical Oncology, Leukemia, Blood and many others. He has authored several books and book chapters in prestigious publications such as Cancer Medicine and Harrison's Principles of Internal Medicine. He has received numerous awards including the Faculty Scholar Award from MD Anderson in 2003, the Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology in 2005, The Dr. John J. Kenny Award from The Leukemia & Lymphoma Society in 2007, the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson in 2007, The Professor David Galton Lecture from the Imperial College of London Hammersmith Hospital in London, UK in 2011, the William Randolph Hearst Foundations Faculty Achievement Award in Education in 2013, and The Gerald P. Bodey Award for Excellence in Education in 2014.
Elihu Estey, M.D., is a Professor of Medicine in the Division of Hematology at the University of Washington School of Medicine and a Full Member and Director of AML Clinical Research (non-transplant) Clinical Research Division, Fred Hutchinson Cancer Research Center. Dr. Estey has built a distinguished career in cancer research approaching 40 years of active clinical practice with Acute Myeloid Leukemia ("AML") patients, providing mentorships for many physicians that have risen to prominence in AML, lectured globally to professional audiences on cancer research and published more than 700 articles on hematologic malignancies, specifically on AML. Additionally, Dr. Estey serves on the European Leukemia Net (ELN) guidelines committee for AML and has served as an advisor for AML studies to the Oncology Drugs Advisory Committee ("ODAC") of the U.S. Food and Drug Administration. Dr. Estey's contribution to science include: developed ATRA and Arsenic without chemotherapy for APL newly diagnosed patients, at MD Anderson; subsequently found to be superior to chemotherapy +ATRA, and now the widely accepted treatment for the disease; the first to develop and use FLAG-IDA (fludarabine containing regimen) in AML; and extensive reviewer of AML publications (Blood and JCO) and current Associate Editor of Leukemia. Dr. Estey's education includes an A.B. in Mathematics from Yale University in 1968 and an M.D. from Johns Hopkins University, Baltimore, MD in 1972. Additionally, Dr. Estey's training includes an Intern in Medicine, New York University, Bellevue Medical Center, New York, NY from 1972-73; a Resident in Medicine, New York University, Bellevue Medical Center, New York, NY from 1973-76; as a Chief Resident in Neurology, New York University, Bellevue Medical Center, New York, NY from 1976-78; and as a Fellow, Department of Developmental Therapeutics, University of Texas M.D. Anderson Hospital, Houston, TX from 1978-80.
Recent MBRX News
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) • PR Newswire (US) • 04/18/2024 12:30:00 PM
- Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties • PR Newswire (US) • 04/10/2024 12:30:00 PM
- Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference • PR Newswire (US) • 03/28/2024 02:45:00 PM
- Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity • PR Newswire (US) • 03/27/2024 01:25:00 PM
- Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML • PR Newswire (US) • 03/27/2024 01:05:00 PM
- Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial • PR Newswire (US) • 03/25/2024 11:30:00 AM
- Moleculin Reports Full Year 2023 Financial Results • PR Newswire (US) • 03/22/2024 08:05:00 PM
- Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 03/20/2024 11:30:00 AM
- JPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest News • IH Market News • 03/20/2024 11:15:48 AM
- Moleculin Announces Reverse Stock Split • PR Newswire (US) • 03/19/2024 08:30:00 PM
- Moleculin to Present at the 36th Annual ROTH Conference • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 02:30:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:19:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 02:15:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:36:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:33:22 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/13/2024 05:15:17 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 10:05:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 01:50:30 PM
- Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 • PR Newswire (US) • 01/24/2024 01:50:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/16/2024 10:00:41 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/05/2024 10:15:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:14:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 12:31:57 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM